Filtered By:
Condition: Diabetes
Nutrition: Sodium

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 371 results found since Jan 2013.

Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
We describe the prevalence, hazard ratios (HRs), and population-attributable fractions (PAFs) for cardiovascular disease and mortality associated with a cluster of behavioural factors (ie, tobacco use, alcohol, diet, physical activity, and sodium intake), metabolic factors (ie, lipids, blood pressure, diabetes, obesity), socioeconomic and psychosocial factors (ie, education, symptoms of depression), grip strength, and household and ambient pollution. Associations between risk factors and the outcomes were established using multivariable Cox frailty models and using PAFs for the entire cohort, and also by countries grouped ...
Source: The Lancet - September 3, 2019 Category: General Medicine Source Type: research

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
ConclusionApproximately one-third of patients with T2DM in the UK have concomitant CVD.FundingMerck Sharp& Dohme Corp., a subsidiary Merck& Co., Inc., Kenilworth, NJ, USA.
Source: Diabetes Therapy - October 3, 2019 Category: Endocrinology Source Type: research

Let Plants be Thy Medicine – You Are What You Eat
Credit: Busani Bafana/IPSBy Esther Ngumbi and Ifeanyi NsoforILLINOIS, United States / ABUJA, Oct 16 2019 (IPS) United Nations World Food Day is celebrated around the world on October 16 under the theme: “Our Actions ARE Our Future. Healthy Diets for a Zero Hunger World”. This theme is timely, especially, because across Africa and around the world, there has been a gradual rise in malnutrition and diet-related non communicable diseases, as highlighted in The Lancet study and a United Nations Report published earlier this year. While 45 percent of deaths in children are from nutrition-related causes, mainly malnu...
Source: IPS Inter Press Service - Health - October 16, 2019 Category: International Medicine & Public Health Authors: Esther Ngumbi and Ifeanyi Nsofor Tags: Food & Agriculture Global Headlines Health World Food Day Source Type: news

Sodium –Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events, including cardiovascular death, non-fatal MI and stroke, occurring across Phase II and III diabetes trials.
Source: Radcliffe Cardiology - November 4, 2019 Category: Cardiology Authors: mehul Source Type: research

Cardioprotective diabetes drugs: what cardiologists need to know
In patients with diabetes, where cardiovascular morbidity is highly prevalent, recent cardiovascular outcomes trials have identified therapies in the modern glucagon-like peptide 1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) classes that significantly reduce cardiovascular events. A number of drugs in both classes have demonstrated reductions in the risk of the composite outcome of major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death). In addition, SGLT2i drugs have a substantial impact on hospitalization for heart failure. Because GLP-1RA and SGL...
Source: Cardiovascular Endocrinology - November 8, 2019 Category: Cardiology Tags: Review Articles Source Type: research

Sodium –Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events, including cardiovascular death, non-fatal MI and stroke, occurring across Phase II and III diabetes trials.
Source: Radcliffe Cardiology - November 4, 2019 Category: Cardiology Authors: mehul Source Type: research

The Cardiovascular Effects of SGLT2 Inhibitors
Publication date: Available online 24 September 2019Source: Canadian Journal of DiabetesAuthor(s): Vincent C. WooAbstractIndividuals with type 2 diabetes mellitus can benefit from pharmacotherapies that lower their risk for cardiovascular disease. This review describes the salient findings from sodium-glucose cotransporter-2 (SGLT2) inhibitor cardiovascular outcome trials that serendipitously revealed the cardiorenal benefits of SGLT2 inhibitors in individuals with type 2 diabetes mellitus who either have established cardiovascular disease or multiple cardiovascular risk factors. It also summarizes the findings from other ...
Source: Canadian Journal of Diabetes - November 29, 2019 Category: Endocrinology Source Type: research

Potassium binding for conservative and preservative management of chronic kidney disease
In conclusion, there are new well tolerated and effective K+-binding agents for acutely and chronically managing hyperkalemia.
Source: Current Opinion in Nephrology and Hypertension - November 29, 2019 Category: Urology & Nephrology Tags: NOVEL THERAPEUTIC APPROACHES IN NEPHROLOGY AND HYPERTENSION: Edited by Kamyar Kalantar-Zadeh and Ekamol Tantisattamo Source Type: research

Evidence-based reduction of cardiovascular risk in patients with diabetes.
Authors: Schütt KA Abstract Patients with type 2 diabetes mellitus exhibit a markedly increased propensity to develop cardiovascular diseases, such as myocardial infarction, stroke and heart failure. The results from large cardiovascular outcome trials conducted in recent years with novel hypoglycemic agents, such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists have led to novel therapeutic strategies to reduce the cardiovascular risk in patients with diabetes. This overview article summarizes the evidence derived ...
Source: Herz - December 12, 2019 Category: Cardiology Tags: Herz Source Type: research

Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
Publication date: Available online 24 September 2019Source: Canadian Journal of DiabetesAuthor(s): Vincent C. WooAbstractAdults with type 2 diabetes mellitus can benefit from pharmacotherapies that lower their risk for cardiovascular disease. This review describes the salient findings from sodium-glucose cotransporter-2 (SGLT2) inhibitor cardiovascular outcome trials that serendipitously revealed the cardiorenal benefits of SGLT2 inhibitors in adults with type 2 diabetes mellitus who either have established cardiovascular disease or multiple cardiovascular risk factors. It also summarizes the findings from other phase 3 cl...
Source: Canadian Journal of Diabetes - December 13, 2019 Category: Endocrinology Source Type: research

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
This report summarizes these discussions and the key takeaway messages from this meeting. PMID: 31841369 [PubMed - in process]
Source: Circulation - December 16, 2019 Category: Cardiology Authors: Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Tags: Circulation Source Type: research

Admission glucose level was associated with increased short-term mortality and length-of-stay irrespective of diagnosis, treating medical specialty or concomitant laboratory values.
CONCLUSIONS: Short-term mortality increased substantially with admission hypo- and hyperglycemia for patients both with and without diabetes, irrespective of treating medical specialty, main discharge diagnosis, or concurrent laboratory values. Patients with diabetes (16%) were older, with higher glucose levels at admission, and with a different pattern of the association of admission glucose and mortality. PMID: 31982283 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - January 21, 2020 Category: Internal Medicine Authors: Björk M, Melin EO, Frisk T, Thunander M Tags: Eur J Intern Med Source Type: research

GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.
Authors: Bertoccini L, Baroni MG Abstract The risk of cardiovascular disease (CVD) (myocardial infarction, stroke, peripheral vascular disease) is twice in type 2 diabetes (T2D) patients compared to non-diabetic subjects. Furthermore, cardiovascular disease (CV) is the leading cause of death in patients with T2D.In the last years several clinical intervention studies with new anti-hyperglycaemic drugs have been published, and they have shown a positive effect on the reduction of mortality and cardiovascular risk in T2D patients. In particular, these studies evaluated sodium/glucose-2 cotransporter inhibitors (SGLT2...
Source: Advances in Experimental Medicine and Biology - February 9, 2020 Category: Research Tags: Adv Exp Med Biol Source Type: research

SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Abstract Sodium-glucose co-transporter-2 (SGLT2) inhibitor drugs are effective for treatment of type-2 diabetes mellitus. These medications target the SGLT2 transporter in the proximal convoluted tubule to prevent reabsorption of filtered glucose, resulting in glucosuria. Other clinically meaningful benefits beyond glycemic control include reductions in blood pressure, weight, and albuminuria. Three large clinical trials and subsequent meta-analyses studying SGLT2 inhibitors demonstrated significant cardiovascular benefits including reductions in heart failure hospitalizations, as well as reduced risk of myocardia...
Source: Journal of Nephrology - February 17, 2020 Category: Urology & Nephrology Authors: Baker ML, Perazella MA Tags: J Nephrol Source Type: research

Our Diets Are Changing Because of the Coronavirus Pandemic. Is It for the Better?
The coronavirus pandemic has changed a lot about modern American life: how we work, socialize, and even how we eat. Dining out is a distant memory. But nutritionally, people weren’t exactly thriving in pre-pandemic America. “Before COVID-19 came along, it was increasingly clear that the diet quality and nutritional status of Americans was terrible,” says Dr. Walter Willett, professor of epidemiology and nutrition at Harvard T.H. Chan School of Public Health. More than 40% of U.S. adults are obese. After years of declines, heart disease death rates are on the rise again. So are rates of obesity-linked canc...
Source: TIME: Health - April 28, 2020 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized COVID-19 Source Type: news